Generic Market Report

It's the world standard reference on the generic drug industry the most thorough business review of every aspect of the global generics drug market...






Generic Market Report 2010

Home >> Products >> Generic Market Report 2010

 


Generic market 2010

A complete survey of the market, company and product prospects in this dynamic industry

Consolidation continues as US companies expand
Corporate consolidation continues to change the operating landscape, most notably the move by US company Mylan in its acquisition of Merck Generics and recent purchase of Arrow. These developments mark a more international shift in the US market and reflects growing price pressure in the domestic market.

EU gets tough on anti-competitive practice
Anxieties about anti-competitive practices in many European markets has seen the EU authorities take action, with a number of company offices raided as allegations are investigated. As recently as October 2009 it has been reported that many companies, including Sandoz, Teva and Ranbaxy have been the subject of such action.

Opportunities over the next 3 years look very promising
The generic sector is set for a boost as patents on a number of high-profile blockbuster products expire. Lipitor, Zyprexa, Actos, Avandia, Cymbalta and Plavix are just some of the leading brands likely to be challenged in the next few years.

Key company, market and product information
To understand the generic market, Espicom, publisher of the respected twice-monthly business publication World Generic Markets, has published The World Generic Market Report 2010. Packed with facts, figures, analysis and statistics, the new 2-volume 680-page edition provides the most thorough analysis available on generic markets, products and companies, and the issues they face.

Industry consolidation, new market/product opportunities, the latest on biosimilars plus much more!
Published in January 2010, this leading report, now in its 8th year of edition, draws on primary research with companies, statistics offices, health ministries and trade associations worldwide and provides standard, comparative data and discussion on key issues such as:

bullet Which products are in the sights of the generic industry?
bullet US regulatory progress – assessing the impact of the Obama reforms
bullet Who is affected by the EU’s anti-competitive investigation, and what are the issues surrounding the allegations?
bullet Who is involved in the latest legal challenges and litigation?
bullet The political, regulatory and funding background in key markets
bullet How generic companies are faring in the recession

Cancer Focus provides a monthly review of oncology developments
bullets Cardiovascular Focus provides a monthly news review for the cardiovascular drug and device industries selected from Espicom's news services;
bullets CNS Focus provides a monthly news review covering major CNS areas such as Neurodegeneration, Alzheimer's disease, Multiple Sclerosis and Depression;
bullets Diagnostic Updates provides a monthly review of industry news on the medical diagnostics;
bullets Drug Delivery Focus provides a monthly review of industry news on leading sectors such as controlled release and targeted drug delivery;
bullets Generics Focus provides a monthly review of generic and biosimilar market and industry news
bullets Orthopaedics Focus is a monthly review of the high-growth high-tech orthopaedics industry ;

    To subscribe to any or our e-newsletters or industry updates, simply complete the form. Please ensure your email address is correct.

    If, for any reason, you change your mind and no longer wish to receive our Intelligence Updates, you will be given the opportunity to 'unsubscribe' with each issue.

 

Taj Drug Pipline